Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis

Tuberculosis
Julia VipondPhilip D Marsh

Abstract

A selection of previously identified protective Mycobacterium tuberculosis DNA vaccines were re-formulated as proteins and administered with a Th1-inducing adjuvant to help stimulate the relevant immune responses necessary for protection. All three candidate-vaccines conferred high levels of antigen-specific cellular and humoral responses, as indicated by lymphocyte proliferation and serum IgG levels. Protective efficacy was also assessed in comparison with the current vaccine, BCG (the 'gold-standard' against which new vaccines are tested), and a saline (negative) control. One candidate (Rv1806-1807) induced protection in the guinea pig aerosol infection model 30 days post-challenge on the basis of reducing the bacterial burden of M. tuberculosis in the lungs.

References

Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·M A HorwitzG Harth
Aug 1, 1996·Nature Medicine·K HuygenJ B Ulmer
Jan 20, 2000·Infection and Immunity·L BrandtP Andersen
Jun 30, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A WilliamsR G Hewinson
Oct 9, 2002·Microbiology·Jean-Christophe CamusStewart T Cole
Jan 28, 2003·Vaccine·Philip J HogarthMark A Chambers
Jun 5, 2003·International Journal for Parasitology·John DonnellyJeffrey B Ulmer
May 10, 2005·Microbes and Infection·Kris Huygen

❮ Previous
Next ❯

Citations

Jun 12, 2009·Journal of Liposome Research·Dennis ChristensenYvonne Perrie
Apr 1, 2009·Microbiology·Roberta ProvvediRiccardo Manganelli
Feb 13, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kee Woong KwonSung Jae Shin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.